Dactinomycin is an antineoplastic agent that inhibits DNA, RNA and protein synthesis. It is used in treatment protocols for many cancers including gestational trophoblastic neoplasia, rhabdomyosarcoma and Wilms tumour (nephroblastoma).
EML status history
Added in 1984 (TRS 722) for Malignant neoplasms of kidney, except renal pelvis
Added in 1984 (TRS 722) for Unspecified malignant neoplasms of ill-defined or unspecified sites
Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites
Therapeutic equivalent for
- Parenteral > General injections > IV: 500 µg in vial powder for injection